After this morning's great discussion at the #epidemiology interest group, Prof Nagy gives a summary of the @eular_org Definition of difficult-to-treat #RheumatoidArthritis at #EULAR2021, including a great summary of the elements and evidence behind the recommendation. https://t.co/imXECTlUbf

Following this morning's excellent group discussion on #D2T #RA, Prof Nagy presents @eular_org Definition of #difficulttotreat RA at #EULAR2021 D2T disease, consider: 👉🏼Treatment history 👉🏼Presence of one of the below factors 👉🏼Mx of difficult signs/symptoms as per clinician https://t.co/xbtKuvjLw4

Dr Lam presenting data on early RA and matched controls. T2T strategy led to no increased CV event risk over 5 years. Longer remission duration protective, higher baseline HAQ associated with higher risk @RheumNow #EULAR2021 Abstr#OP0103 https://t.co/MZdEoyWI64

We are truly blessed to live in an era when response to RA treatment is the norm. (our forefathers looking on jealously from their gold and pencillinamine towers!) real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv

tofa/bari in RA H2H vs TNFi comparative efficacy studies highlighted (more head-to-head studies please!) @karolinskainst OP0122 #EULAR2021 @RheumNow (also Swedish national registry data showed tofa/bari comparable to non-TNFi bDMARDs, but no photos allowed!) https://t.co/CUWlK2O94h

VTE/VZV in baricitinib & tofacitinib seem unrelated to on-target effects. Is there VTE/VZV-related off-target culpable binding? Computer (AI) says no, but... bari binds PDE10A2 (an antipsychotic target), lab confirmed. Missing link to reduced pain? POS0091 #EULAR2021 @RheumNow https://t.co/uqYixHhW1z

Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw

#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN

#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF

Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhood or adulthood could be found as risk factor for #RA and potentially earlier onset #OP0012 #EULAR2021 @RheumNow https://t.co/58DJ8lZzfV

Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO

Data from E3N-EPIC cohort: passive tabagism in both childhood (HR 1.42 95CI [1.07 to 1.88]) and adulthood (HR 1.27 95CI [1.02 to 1.57]) associated with higher risk of RA in non smoking women (adjusted on age passive smoking educational level BMI) #EULAR2021 @RheumNow #OP0012

Towards personalized therapy in RA with @MeganHanlon4's work: the synovial macrophage sub-population CD206+CD163+ is significantly enriched in RA synovial tissue, correlated with disease activity and baseline levels predict response to therapy. #EULAR2021 @RheumNow #OP0028

Insights in RA and colon: Naïve RA patients -higher degree of intestinal permeability vs age and sex matched ctrls in colonic biopsies -higher serum levels of bacterial translocation markers (LBP and CD14s); reduced in resp to DMARDs. #EULAR2021 @RheumNow #OP0035 @ClaireDaien